Phrixus Pharmaceuticals' Convertible Note Round

Phrixus Pharmaceuticals raised a round of funding on July 31, 2007.

Phrixus Pharmaceuticals is developing Carmeseal (poloxamer 188 or P188) for Duchenne muscular dystrophy and acute decompensated heart failure. Carmeseal has been shown to improve the efficiency of dam…

Articles about Phrixus Pharmaceuticals' Convertible Note Round: